Sequenom Center for Molecular Medicine, LLC develops a range of molecular genetic laboratory tests with a focus on prenatal and ophthalmological diseases and conditions. The company offers MaterniT21 PLUS test for fetal aneuploidies that analyzes the relative amount of 21, 18, 13, X and Y chromosomal material in circulating cell-free DNA from a maternal blood sample; Heredi-T cystic fibrosis carrier screen test that detects a phenotypically-confirmed panel selected from the John Hopkins CFTR2 database; SensiGene fetal RHD genotyping test for the analysis of fetal RHD genotype; and RetnaGene AMD test for age-related macular degeneration. Its laboratory tests provide early patient management i...
301 Michigan Street NE
Grand Rapids, MI 49503
Sequenom Center for Molecular Medicine, LLC Enters into Agreement for Services with Quest Diagnostics Incorporated to Provide its MaterniT21 Plus Laboratory-Developed Test Service
Jun 16 14
On June 13, 2014, Sequenom Inc., through its wholly-owned subsidiary Sequenom Center for Molecular Medicine, LLC (SCMM), entered into an agreement for services with Quest Diagnostics Incorporated, pursuant to which SCMM will provide its MaterniT21 PLUS laboratory-developed test service to Quest, and has agreed to provide a related laboratory-developed test service to Quest in the future following its commercialization (such related future test service, the Future Testing Service, and together with the MaterniT21 PLUS laboratory-developed test service, the Testing Services). After an initial period following the execution of the services agreement through the term of the services agreement, Quest has agreed not to order from or contract with any other laboratory, other than SCMM, for the provision of non-invasive prenatal testing services for or on behalf of Quest's physician customers and their patients (the Quest Exclusivity) and SCMM has agreed not to provide or contract with any third party laboratory that has securities that are traded on a public stock exchange with annual revenues greater than one billion dollars for the testing services. Notwithstanding the foregoing, in the event that the Future Testing Service is not commercialized by SCMM by a date sometime in the fourth quarter of 2014, then the Quest Exclusivity shall immediately terminate. Pursuant to the services agreement, Quest has agreed to pay SCMM a fixed fee for each Testing Service performed by SCMM on Quest's behalf. The services agreement has a term of two years, but shall automatically renew for additional terms of one year each unless either party provides at least 60 days prior written notice to the other party; provided, however, that the services agreement can be earlier terminated by the mutual agreement of the parties, by a party upon an uncured material breach of the services agreement by the other party, by Quest if any action is taken against SCMM to revoke, suspend or terminate any license to operate a clinical laboratory or to revoke, suspend or terminate SCMM’s participation in Medicaid, Medicare or other federally funded programs, and such action is not resolved within 90 days, or by Quest if the testing services are determined by a court to infringe the intellectual property of a third party and SCMM has not obtained the rights necessary to enable Quest to continue to use the testing Services or an alternative and comparable testing service.
Sequenom Center for Molecular Medicine Launches the Enhanced Sequencing Series for the MaterniT21(TM) PLUS Test
Oct 22 13
Sequenom Center for Molecular Medicine has launched the Enhanced Sequencing Series for its MaterniT21(TM) PLUS laboratory-developed test (LDT). The MaterniT21 PLUS test will begin reporting additional findings for the presence of subchromosomal microdeletions and autosomal trisomies for chromosomes 16 and 22, in addition to the previously announced additional findings for sex chromosome aneuploidies involving an abnormal number of the X or Y chromosomes. These additional findings complement the MaterniT21 PLUS test core identification of trisomies for chromosome 21, chromosome 18 and chromosome 13. With this expansion, the MaterniT21 PLUS test is the first-of-its-kind noninvasive prenatal technology (NIPT) to provide these comprehensive results from a maternal blood draw. Sequenom Laboratories will begin reporting on these select, clinically relevant microdeletions, including 22q11.2 deletion syndrome, Cri-du-chat syndrome, Prader-Willi/Angelman syndrome, 1p36 deletion syndrome, as well as trisomies 16 and 22 the last week of October. Results from a method validation study demonstrated high performance of the MaterniT21 PLUS test in accurately detecting these autosomal trisomies and select microdeletions.